EC
ACRS icon

EntryPoint Capital’s Aclaris Therapeutics ACRS Stock Holding History

EntryPoint Capital’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-33,007
Closed -$124K – 772
2026
Q1 		$124K Buy
+33,007
New +$111K 0.04% 689

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

EntryPoint Capital's ACRS Position: Q2 2026 in Review

EntryPoint Capital sold out of Aclaris Therapeutics (ACRS) in Q2 2026, closing a stake of 33,007 shares — an estimated $124K sold.

EntryPoint Capital first reported a position in ACRS in Q1 2026 and held it in 1 quarter. The position peaked at $124K in Q1 2026. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • EntryPoint Capital reported no remaining Aclaris Therapeutics position as of Q2 2026 after selling out during the quarter.
  • EntryPoint Capital sold 33,007 Aclaris Therapeutics shares in Q2 2026, an estimated $124K.
  • EntryPoint Capital first reported a position in Aclaris Therapeutics in Q1 2026 and held it in 1 quarter.
  • EntryPoint Capital's Aclaris Therapeutics position peaked at $124K in Q1 2026.
  • 149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.